Syngene International Limited Announces Leadership Changes
Syngene International Limited announced changes to its leadership structure on March 27, 2026. The Board of Directors approved Kiran Mazumdar Shaw’s transition from Non-Executive Chairperson to Executive Chairperson, effective April 1, 2026, for a period of 5 years. Simultaneously, Peter Bains resigned from his position as Managing Director & Chief Executive Officer, effective June 30, 2026. Siddharth Mittal has been appointed as an Additional Director, assuming the roles of Managing Director & Chief Executive Officer, and joining the Executive Committee, starting July 1, 2026, for a term of 5 years.Siddharth Mittal previously served as Managing Director and CEO of Biocon Limited, a role he held since May 2013. Prior to that, he served as President & Chief Financial Officer of Biocon Limited from May 2013 to November 2019. His experience includes strategic finance, mergers and acquisitions, and general management, contributing to the growth of the biosimilars business and the company's entry into complex peptides, GLP-1 therapies, and generic formulations.
Brief Profiles:
Kiran Mazumdar Shaw: Founder of Biocon Group, with over four decades of experience in biotechnology.
Siddharth Mittal: Previously Managing Director and CEO of Biocon Limited.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.